📰 #USMIRC Newsletter: Issue 3/ 5 Jan 2025 

- Teclistamab in relapse refractory myeloma in real-world
- Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma
-USMIRC Medal Awards winners
2024
- USMIRC group Social Media posts
- AQUILA Trial: Daratumumab for High-Risk Smoldering Multiple Myeloma
- USMIRC January Image
- History of myeloma Therapies time-line
#mmsm #myeloma #medtwitter #MedEd
#USMIRC